; and (2) by striking paragraph (1) of section 1302(c) and inserting paragraphs (1) and (5) of section 1302(c) of the Patient Protection and Affordable Care Act . (c) Effective date The amendments made by subsections (a) and (b) shall take effect with respect to plans beginning after December 31, 2019. III Innovation 301. Prize fund for new and more effective treatments of bacterial infections Part B of title IV of the Public Health Service Act ( 42 U.S.C. 284 et seq.) is amended by adding at the end the following: 409K. Prize fund for new and more effective treatments of bacterial infections (a) Establishment of fund There is hereby established in the Treasury of the United States a revolving fund to be known as the Antibiotics Prize Fund , which shall consist of funds transferred under subsection (b). (b) Amounts credited to the fund There are hereby authorized to be appropriated, and appropriated, to the Antibiotics Prize Fund, for fiscal year 2020, out of any monies in the Treasury not otherwise appropriated, $2,000,000,000. Such funds shall remain available until expended. (c) Awards (1) In general During the 10-year period following the date of enactment of the Affordable Medications Act , the Director of the NIH, in accordance with the criteria under subsection (d) and the goals under subsection (e), shall award— (A) up to 3 prizes for qualifying products that provide added benefit for patients over existing therapies in the treatment of serious and life-threatening bacterial infections demonstrating in superiority trials